Zolbetuximab is a claudin-18.2-directed monoclonal antibody used in combination with platinum- and fluoropyrimidine-containing chemotherapy for advanced HER2 negative, CLDN18.2-positive gastric and GEJ cancers. Zolbetuximab (previously claudiximab) is a chimeric cytolytic antibody comprising variable regions derived from mouse anti-human claudin-18 isoform 2 monoclonal antibody and constant regions derived from human IgG1.
- Mechanism
- Curator reviewed · 3 references
In healthy tissues, claudin 18 protein, particularly its isoform 2 (i.e. CLDN18.2), is expressed only in the gastric mucosa. Its expression is retained during transformation to malignant gastric cancer cells, which leads to exposure of CLDN18.2 protein on the cell surface due to damage in cell polarity.
Zolbetuximab is a chimeric cytolytic antibody that exhibits high sensitivity and specificity for the CLDN18.2 protein. It attaches to CLDN18.2 on the surface of tumour cells and stimulates both cellular and soluble immune effectors, which in turn triggers both antibody- and complement-dependent cytotoxicity.
- Primary indication
- Zolbetuximab is indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin 18.2 positive...Curator reviewed · 4 structured indications
- Formula / weight
- 147000.0 Da
- First approval
- Canada, 2024 · United States, 2024 · European Union, 2024
- Also known as
- Claudiximab · immunoglobulin G1, anti-(human Claudin-18.2) (human-mus musculus monoclonal IMAB362 heavy chain), disulfide with human-mus musculus monoclonal IMAB362 .kappa.-chain, dimer
- Code names
- IMAB-362
Resolves to
What you can answer from here — as of January 10, 2025
Which drugs share a target with Zolbetuximab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account